NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
Clinical Trials
12 trialsNCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT05833724 2025-03-11
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 2 Recruiting
NCT05281276 2024-12-20
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
Taipei Medical University Shuang Ho Hospital
Phase 1 Terminated
NCT02953652 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
Phase 2 Completed
NCT02955589 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
HUYABIO International, LLC.
Phase 2 Completed
NCT02718066 2023-11-09
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
HUYABIO International, LLC.
Phase 1/2 Completed
NCT02569489 2022-07-18
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
HUYABIO International, LLC.
Phase 1 Withdrawn
NCT03201471 2018-08-02
DLBCL
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03605056 2018-07-30
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03336632 2018-07-18
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
Sichuan University
Phase 2 Unknown
NCT02697552 2017-01-12
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
HUYABIO International, LLC.
Phase 1 Completed